Transcenta Therapeutics (Hangzhou) Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING0
READOUTS ≤12 MONTHS4
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Denosumab NCT07806331 |
P2 | Not yet recruiting | Postmenopausal Osteoporosis; Low Bone Mass | 110 | 2027-04-30 |
| TST001 NCT04495296 |
P1/2 | Active, not recruiting | Advanced Cancer | 320 | 2027-06-30 (+58 mo) |
| TST003 NCT05731271 |
P1/2 | Active, not recruiting | Locally Advanced Solid Tumor; Metastatic Tumor | 111 | 2027-06-30 (+26 mo) |
| TST001 NCT04396821 |
P1/2 | Active, not recruiting | Advanced Cancer; Gastric Cancer | 150 | 2027-06-30 (+54 mo) |
| Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil NCT06093425 |
P3 | Not yet recruiting | Gastric Cancer; Gastroesophageal-junction Cancer | 820 | 2029-10-01 (+48 mo) |